025sek
-5,0 %
Date:2025-10-10Time:18:00:00Latest report:Q2-2025List:First NorthTicker:NOVKAN
Market Cap:31 msekEnterprise Value:3 msekNet Sales:- msekEarnings:-39,9 msekEmployees:0ISIN:SE0015658570

Ratios

10-year key figure history for Novakand Pharma turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Novakand Pharma with index and moving average MA50 and MA200.

Stockprice:0,25
MA50:0,76
MA200:1,11
Price/MA200:-77,1 %
RSI (14):31,5
Price/MA50:-66,7 %

Description

Novakand Pharma is a pharmaceutical company. The company develops drugs that counteract damage caused by acute and chronic inflammation. The products are mainly developed to counteract hyperinflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe viral infections. Novakand Pharma is planning two clinical phase II studies, in COVID-19 and in heart patients. The company conducts research and development at Karolinska Institutet Science Park in Stockholm.

Pharmaceuticals